Researchers at Oregon Health & Science University (OHSU) have identified and developed a groundbreaking experimental compound that offers a potential new avenue for treating triple-negative breast cancer (TNBC), an exceptionally challenging and often lethal form of the disease. This innovative molecule, designated SU212, operates by targeting a crucial metabolic enzyme overexpressed in cancer cells, thereby disrupting their energy supply and survival mechanisms. The findings, detailed in the peer-reviewed journal Cell Reports Medicine, mark a significant stride in the ongoing quest to develop more effective interventions for malignancies currently lacking targeted therapeutic options.
Triple-negative breast cancer, so named because its cells lack the three most common receptors—estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)—accounts for approximately 10-15% of all breast cancer diagnoses. Unlike other subtypes, TNBC does not respond to hormone therapy or HER2-targeted drugs, leaving patients with limited treatment choices primarily consisting of chemotherapy, radiation, and surgery. Its aggressive nature is characterized by rapid growth, a higher likelihood of metastasis (spread to other parts of the body), and a greater propensity for recurrence post-treatment, often leading to poorer prognoses compared to other breast cancer types. The urgent need for novel, effective therapies for TNBC patients underscores the importance of discoveries like SU212.
The scientific team, spearheaded by senior author Dr. Sanjay V. Malhotra, co-director of the Center for Experimental Therapeutics within the OHSU Knight Cancer Institute, focused their efforts on disrupting the unique metabolic adaptations that allow cancer cells to thrive. "Triple-negative breast cancer is an aggressive form of cancer, and there are currently no sufficiently effective targeted drugs available," Dr. Malhotra emphasized, highlighting the critical unmet medical need his research aims to address. The strategic approach taken by the OHSU team involved targeting enolase 1 (ENO1), an enzyme integral to glycolysis, the metabolic pathway that converts glucose into energy. While essential for normal cellular function, ENO1 is often found in unusually high concentrations in various cancer cells, including those of TNBC, suggesting it plays a hyper-active role in fueling tumor growth and proliferation.
In healthy cells, ENO1 acts as a metabolic facilitator, efficiently processing glucose to generate adenosine triphosphate (ATP), the primary energy currency of the cell. However, cancer cells exhibit a phenomenon known as the Warburg effect, where they preferentially rely on glycolysis even in the presence of oxygen, a less efficient but faster method of energy production, to support their rapid growth and division. This metabolic shift makes enzymes like ENO1 particularly vulnerable targets. The experimental molecule SU212 is designed to precisely bind to ENO1. Upon binding, SU212 initiates a cascade of events that ultimately lead to the degradation and breakdown of the enzyme itself. This disruption effectively cripples the cancer cell’s ability to metabolize glucose, starving it of the energy required for survival and replication.
The efficacy of SU212 was rigorously evaluated using a sophisticated humanized mouse model of triple-negative breast cancer. These models are meticulously engineered to mimic human disease conditions as closely as possible, providing a critical preclinical bridge between laboratory discoveries and potential human applications. In these animal studies, the targeted degradation of ENO1 by SU212 demonstrated compelling results: a significant reduction in tumor growth and a notable limitation of metastatic spread. Metastasis, the process by which cancer cells detach from the primary tumor and migrate to form secondary tumors in distant organs, is the leading cause of cancer-related mortality. Interfering with this process is a paramount goal in oncology, and SU212’s ability to limit it represents a highly promising outcome.
The implications of this metabolic targeting strategy extend beyond TNBC. Dr. Malhotra, who also holds the Sheila Edwards-Lienhart Endowed Chair in Cancer Research and is a professor of cell, developmental, and cancer biology in the OHSU School of Medicine, posits that this mechanism could be broadly applicable to other malignancies that similarly exploit ENO1 for their metabolic advantage. Preliminary investigations suggest that cancers such as glioma (a type of brain tumor), pancreatic cancer, and thyroid carcinoma also exhibit elevated ENO1 levels, making them potential candidates for therapies employing a similar inhibitory approach. "A drug that targets enolase 1 could help improve the treatment of these cancers too," Dr. Malhotra remarked, envisioning a wider impact for this class of therapeutic agents.
Furthermore, the research highlights a fascinating intersection between cancer biology and metabolic disorders. Dr. Malhotra noted that this specific mechanism of action might hold particular relevance for cancer patients who also grapple with metabolic conditions like diabetes. Diabetes, characterized by chronically high blood sugar levels, significantly alters cellular glucose metabolism. While the precise interplay between cancer metabolism and systemic metabolic disorders is complex and an active area of research, a drug that directly interferes with glucose utilization pathways could offer synergistic benefits or tailored treatment strategies for this patient subgroup.
The journey from a laboratory discovery to a clinically viable medicine is a long and arduous one, requiring immense resources and navigating stringent regulatory pathways. The next critical phase for SU212 involves advancing it toward human clinical trials. This multi-stage process necessitates securing approval from the U.S. Food and Drug Administration (FDA) to initiate studies involving patients, a process that evaluates the compound’s safety, dosage, and efficacy in humans. Clinical trials are typically conducted in three phases: Phase 1 focuses on safety and optimal dosing in a small group of volunteers, Phase 2 assesses efficacy in a larger group of patients with the target condition, and Phase 3 compares the new treatment against existing standards of care in an even larger patient population. Each phase requires substantial investment in time, funding, and infrastructure, underscoring the collaborative effort required to translate scientific breakthroughs into tangible patient benefits.
Dr. Malhotra’s work on this molecule has a rich history, beginning at the National Cancer Institute in Bethesda, Maryland, where the compound was originally conceived. His research continued at Stanford University before he joined OHSU in 2020. At the OHSU Knight Cancer Institute, a globally recognized leader in cancer research and treatment, Dr. Malhotra and his colleagues are dedicated to translational science – the process of transforming laboratory discoveries into clinical applications that directly improve patient outcomes. The Institute’s mission aligns perfectly with the current research, emphasizing the importance of moving cutting-edge science from the bench to the bedside, benefiting patients treated within OHSU hospitals and clinics. "There is definitely great science going on here, and we want to translate that science for the benefit of people," Dr. Malhotra affirmed, encapsulating the driving philosophy behind their relentless pursuit of new cancer therapies.
This pivotal research was made possible through the generous support of several key funding bodies, reflecting a broad commitment to advancing cancer research. Major contributions came from the National Cancer Institute, the National Institute of Aging, and the National Heart, Lung and Blood Institute, all components of the National Institutes of Health, under specific award numbers. Further vital support was provided by the Department of Defense, the OHSU Knight Cancer Institute, the Biomedical Innovation Program at OHSU, and Sheila Edwards-Lienhart endowment funds. These diverse funding sources underscore the collaborative and multidisciplinary effort required to propel innovative scientific discoveries forward, ultimately paving the way for potentially life-saving treatments for patients confronting aggressive cancers like triple-negative breast cancer.
About the Author
